

Table SI. Adverse events during treatment with pembrolizumab-carboplatin-paclitaxel for each individual patient.

Patient order no.	Event type and grade				
	G1	G2	G3	G4	G5
1	Peripheral neuropathy	Asthenia, anorexia, alopecia, anemia, trombopenia, respiratory infection	(-)	(-)	(-)
2	Peripheral neuropathy	Asthenia, anorexia, alopecia, anemia, thrombopenia, respiratory infection	(-)	(-)	(-)
3	Anemia, hypomagnesemia	Neutropenia asthenia seromucous otitis	Neutropenia, Hypertensive crisis	(-)	(-)
4	Peripheral neuropathy	Asthenia, anorexia, alopecia	Neutropenia, Thrombopenia	(-)	(-)
5	Peripheral neuropathy	Asthenia, anorexia, alopecia, anemia, trombopenia, respiratory infection	(-)	(-)	(-)
6	Peripheral neuropathy	Asthenia, anorexia, alopecia, anemia, trombopenia, respiratory infection	(-)	(-)	(-)
7	Peripheral neuropathy	Asthenia, anorexia, alopecia	(-)	(-)	(-)
8	Peripheral neuropathy	Asthenia, anorexia, alopecia	(-)	(-)	(-)
9	Asthenia, tumor ulcer infection	Peripheral neuropathy	(-)	(-)	(-)
10	Hypomagnesemia, thrombopenia	Alopecia, asthenia, nausea, anemia, anorexia	Hypomagnesemia	(-)	(-)

Event grading according to Common Terminology Criteria for Adverse Events version 4.1. G, grade; (-), not applicable.

Table SII. Treatment compliance during treatment with pembrolizumab-carboplatin-paclitaxel for each individual patient.

Patient	Pembrolizumab combination				Carboplatin						Paclitaxel						Maintenance pembrolizumab			
	Dose, mg/m <sup>2</sup>	Cycles	Delayed cycles	Mean delay, days	Initial dose, mg/d (Mean dose received, mg/m <sup>2</sup> )	Cycles	Cycles with dose reduction	% of dose reduction	Delayed cycles	Mean delay, days	Initial dose, mg/m <sup>2</sup> (mg/d) : Mean dose received, mg/m <sup>2</sup>	Cycles	Cycles with dose reduction	% of dose reduction	Delayed cycles	Mean delay, days	Dose, mg/m <sup>2</sup>	Cycles	Delayed cycles	Mean delay, days
1	200	2	0	0	AUC 2 176 (108)	2	1	32	0	0	80 (132): 80	2	1	30	1	0	200	2	0	0
2	200	3	0	0	AUC 3 200 (137)	1	0	0	0	0	80 (112): 77	2	1	12.5	0	0	200	0	0	0
3	200	11	1	7	AUC 4 337 (200)	11	7	23	1	7	150 (184): 110	11	7	33	1	7	200	0	0	0
4	200	6	0	0	AUC 4 337 (216)	6	2	18	0	0	150 (193): 124	6	2	13	0	0	200	25	2	7
5	200	3	0	0	AUC 2 327 (177)	3	0	0	0	0	60 (106): 60	3	0	0	0	0	200	0	0	0
6	200	6	0	0	AUC 3 300 (167)	6	0	0	0	0	90 (156): 90	6	0	0	0	0	200	1	0	0

7	200	2	0	0	AUC 3 250 (152)	2	0	0	0	0	125 (202): 125	2	0	0	0	0	200	0	0	0
8	200	1	0	0	AUC 3 400 (239)	1	0	0	0	0	150 (250): 150	1	0	0	0	0	200	0	0	0
9	200	6	2	14	AUC 4 552 (302)	6	0	0	2	14	150 (240): 150	6	0	0	2	14	200	1	0	0
10	200	6	1	7	AUC 4 300 (212)	6	0	0	1	7	150 (150): 150	6	0	0	1	7	200	1	0	0

AUC, area under the concentration curve; CBDCA, carboplatin.

Table SIII. Association and correlation between programmed death-ligand 1 expression and efficacy of pembrolizumab-carboplatin-paclitaxel.

A, Pembro + CP (n=10)				
Variable	Association <sup>a</sup>		Correlation <sup>b</sup>	
	TPS	CPS	TPS	CPS
ORR	P=0.397	P=0.886	(-)	(-)
PFS	P=1.000	P=1.000	r=0.062	τ=0.203
OS	P=1.000	P=1.000	r= -0.037	τ=-0.073
B, Pembro + 3wkCP (n=8)				
Variable	Association <sup>a</sup>		Correlation <sup>b</sup>	
	TPS	CPS	TPS	CPS
ORR	P=1.000	P=1.000	(-)	(-)
PFS	P=1.000	P=1.000	r=0.345	τ=0.431
OS	P=1.000	P=1.000	r=0.265	τ=0.077

<sup>a</sup>Fisher's exact test was used to evaluate any association between PDL1 expression and response and survival in the whole population (n=10) and in patients treated with pembro + 3wkCP (n=8). <sup>b</sup>Pearson's Correlation Test was used to evaluate any correlations between the TPS and survival and Kendall's Correlation Test was used to evaluate any correlation between the CPS and survival. (-), not applicable; 3wkCP, 3-weekly carboplatin-paclitaxel; CPS, combined positive score; ORR, overall response rate; OS, overall survival; pembro + CP, pembrolizumab-carboplatin-paclitaxel; pembro, pembrolizumab; PFS, progression-free survival; TPS, tumor proportion score.